In clinical practice, few retrospective studies have shown that trastuzumab-based therapies improve survival in patients with HER2-positive breast cancer with brain metastases, although, this survival benefit is largely due to extracranial disease control [25,26]. This evidence concerns the gene ERBB2 and breast carcinoma.